Introduction
============

The Japanese Society for Neuroendovascular Therapy (JSNET) conducted a "Study for preparing guidelines for safe catheter intervention and physician training: Japanese Registry of Neuroendovascular Therapy (JR-NET1)" to investigate the general status of neuroendovascular therapy in Japan, with patients enrolled in 2005 and 2006.^[@B1]^ JR-NET1 was followed by a "Study for construction and efficacy of education and training systems for catheter intervention: JR-NET2 and 3," and patients who underwent neuroendovascular therapy between 2007 and 2009 were included in JR-NET2, while those who underwent treatment between 2010 and 2014 were included in JR-NET3. In this article, the current status of the endovascular treatment of spinal vascular lesions in Japan will be reviewed based on the results of JR-NET2 and 3. Our previous report mentioned the current status of endovascular treatment for all spinal vascular lesions in Japan. In this study, we focused on SDAVF, which is the most common spinal vascular lesion, and parameters such as patient characteristics and treatment outcome were analyzed.^[@B2]^

Subjects and Methods
====================

JR-NET2 included all patients treated by JSNET board-certified physicians between January 2007 and December 2009 ([Fig. 1](#F1){ref-type="fig"}). Medical information of the patients was anonymized and registered. JR-NET3 included and registered between January 2010 and December 2014 in the same manner. Data were collected at the Translational Research Informatics Center (<http://www.tri-kobe.org/>). The study protocol, which is summarized briefly here, is available online with the full text of this article (<https://jr-net.tri-kobe.net/jr-net/>).

A total of 122 spinal lesions were included in JR-NET2. After excluding two lesions with incomplete data for multiple registration parameters or the primary endpoint, 120 spinal vascular lesions were analyzed: 55 cases of spinal dural arteriovenous fistula (SDAVF), 31 cases of spinal perimedullary arteriovenous fistula (SPAVF), and 17 cases of spinal intramedullary arteriovenous malformation (SIAVM) A total of 229 spinal lesions were included in JR-NET3. After excluding two lesions with incomplete data, the following 227 vascular lesions were analyzed: 117 cases of SDAVF, 53 cases of SPAVF, and 18 cases of SIAVM. All the data from JR-NET2 and 3 were combined for analysis. In this study, we focused on SDAVF, and parameters regarding patient characteristics and the treatment outcome of SDAVF were analyzed, including sex, age, pre-treatment modified Ranking Scale (mRS) score, location, number of feeders, embolic material, technical success, treatment-related complications, postoperative neurological findings, mRS ≤ 2 on day 30, symptomatology, treatment strategy, and obliteration of shunt. A Chi-square test was used to determine the correlation between each variable except for age and the primary endpoint, defined as a mRS score of 0--2 on day 30 and postoperative neurological improvement. The Student's *t*-test was used to compare age. Subsequently, a multivariate analysis (logistic regression analysis) was performed, including variables with a probability value (*P*) of \<0.1 in the Chi-square test, sex, and age. A significance level of *P* ≤0.05 was used. SPSS Statistics Version 20 software (IBM SPSS, Chicago, IL, USA) was used for the statistical analysis.

Results
=======

Characteristics of SDAVF
------------------------

Spinal dural arteriovenous fistula was more common among elderly patients (mean age: 62.5 ± 15 years) and men (77.3%) ([Table 1](#T1){ref-type="table"}). A pre-treatment mRS score of 0--2 in 66.3% of the SDAVF cases suggested a pre-treatment deterioration in activities of daily living (ADL). Regarding the location, SDAVF affected the neck region in 24 cases (14.0%) and the thoracolumbosacral region in 148 cases (86%). A single feeder was present in 48% of the cases. Regarding symptomatology, 153 cases (89.0%) were non-hemorrhagic, 15 cases (8.7%) were hemorrhagic, and only three cases (1.7%) were asymptomatic.

Treatment of SDAVF
------------------

A curative treatment strategy was adopted in the majority of cases (79.1%). *N*-butyl-cyanoarrylate was the most common embolic material. Technical success was achieved in 90.1% of the cases, and obliteration of the shunt was achieved in 57.0%. Treatment-related complications occurred in 12 cases (7.0%), including three cases with vessel perforation, two with draining vein occlusion, two with distal embolism, two with normal vessel occlusion, and three other cases. Symptomatic complications occurred in five cases (2.9%). Postoperative neurological improvement was achieved in 48.3% of the patients. The primary endpoint, defined as a mRS score of 0--2 on day 30, was achieved in 60.5% of the cases.

Cervical SDAVF
--------------

Spinal dural arteriovenous fistula affecting the cervical region was seen in one out of 55 cases (1.8%) in JR-NET2 and 23 out of 117 cases (19.7%) in JR-NET3, representing an obvious increase in incidence. Compared with non-cervical SDAVF, cervical SDAVF was characterized by a higher proportion of women (*P* = 0.03). A pre-treatment mRS score of 0--2 was more common among cervical SDAVF patients than among those with non-cervical SDAVF (*P* = 0.03). Regarding symptomatology, a hemorrhagic onset was more common among cervical SDAVF than among non-cervical SDAVF (*P* \<0.01). Radical embolization was less common than that for non-cervical SDAVF (*P* = 0.03). Complete obliteration of the shunt was less common (*P* \<0.01), and the rate of complications was higher (*P* = 0.01), compared with non-cervical SDAVF. The postoperative neurological improvement rate was also lower than that for non-cervical SDAVF (*P* = 0.03).

Prognostic factors for SDAVF
----------------------------

A mRS score of 0--2 on day 30, which was the primary endpoint of this study, was the only factor correlated with a pre-treatment mRS of 0--2 (*P* \<0.01) in univariate analyses ([Table 2](#T2){ref-type="table"}). Postoperative neurological improvement was correlated with a non-cervical region (*P* = 0.01), a non-hemorrhagic onset (*P* = 0.01), radical embolization (*P* \<0.01), and complete obliteration of the shunt (*P* \<0.01) in univariate analyses. Complete obliteration of the shunt was the only factor that was correlated with a postoperative neurological improvement in a multivariate analysis (*P* = 0.001) ([Table 3](#T3){ref-type="table"}).

Discussion
==========

Spinal dural arteriovenous fistula was most commonly observed in the thoracolumbar spine of middle-aged and older men with non-hemorrhagic onset,^[@B3]--[@B5]^ as previously reported. Endovascular treatment was safely performed for SDAVF. A new finding of this study is that the incidence of cervical lesions, which have more aggressive features than non-cervical lesions, had obviously increased in JR-NET3, compared with JR-NET2.

Characteristics and treatment outcome of SDAVF
----------------------------------------------

Spinal dural arteriovenous fistula is the most common spinal vascular lesion^[@B3],[@B6],[@B7]^ and predominantly affects the thoracolumbar spine in middle-aged and older males, typically with a non-hemorrhagic onset in the majority of cases, as previously reported. Most non-hemorrhagic symptoms are caused by venous congestion, and early shunt obliteration can alleviate symptoms.^[@B8]^

Several reports have described the use of endovascular treatment to cure SDAVF.^[@B7],[@B9]^ The rate of complete obliteration with liquid embolic agents is reported to be 55--90%.^[@B7],[@B9]--[@B13]^ Treatment-related complications are 3.7--6.9%.^[@B14],[@B15]^ As for postoperative neurological improvement, gait improvement is reported to be 40--100%,^[@B7],[@B9],[@B12]^ while urinary symptoms and sensory disturbance are less likely to improve.^[@B7]^

In the present study, total shunt obliteration was achieved in 54% of the cases, while subtotal obliteration was attained in an additional 22.1% of the cases. Treatment-related symptomatic complications occurred in 2.9% of the cases. An improvement in symptoms was obtained in 48.3%, and the symptoms were stabilized in 47.1%. Thus, the treatment outcome of the present study was comparable to those of previous reports.

On the other hand, the rate of complete obliteration by surgical treatment is reported to be 83--100%, stably higher than endovascular treatment.^[@B4],[@B5],[@B10],[@B11],[@B13],[@B14]^ Treatment-related complications are reported to be low, ranged from 3.7 to 7.7%.^[@B14],[@B15]^ The rate of improvement or stabilization in neurological symptoms after surgical treatment is reported to be high with 89--93% of SDAVF cases.^[@B12],[@B14]^

Postoperative neurological improvement was correlated with complete shunt obliteration in the presently reported series of patients. The goal of embolization for SDAVF should be complete obliteration. SDAVF is highly curable with surgical treatment and thus should be radically treated if complete obliteration cannot be achieved by endovascular means.^[@B4],[@B5],[@B14]^

The incidence of cervical lesions, which have more aggressive features than non-cervical lesions, obviously increased in JR-NET3, compared with JR-NET2. Postoperative neurological improvement was inversely correlated with occurrence in the cervical region. Since cervical SDAVF has different features, it should be considered separately.

Cervical SDAVF
--------------

Compared with non-cervical SDAVF, cervical SDAVF was characterized by a higher proportion of female patients (*P* = 0.03), a higher proportion of hemorrhagic onset (*P* \<0.01), fewer cases treated with radical embolization (*P* = 0.03), fewer cases with complete obliteration of the shunt (*P* \<0.01), more complications because of embolization (*P* = 0.01), and a smaller degree of post-treatment neurological improvement (*P* = 0.03).

Since spinal vascular lesions in the cranio-cervical junction (CCJ) to the upper cervical level are very complicated, a correct diagnosis might not have been made in many cases. Recently, the inclusion of high-resolution cone-beam CT in angiography machines has become popular, and this modality is very helpful for visualizing the detailed vascular structure. Advancements in imaging modalities may have contributed to the increased detection and recognition of cervical AVFs. Furthermore, disease concept of this area have been spread in Japanese neurosurgeons by educational activities and clinical researches. Hiramatsu et al.^[@B16]^ reported a multicenter cohort study of 54 cases of CCJ AVFs. The authors analyzed the angiographic and clinical data of CCJ AVFs from 20 participating centers belonging to the JSNET. They divided CCJ AVFs into five angiographic types. Among patients with type 1 SDAVF, 82% were men and 50% had a subarachnoid hemorrhage onset. Endovascular surgery was performed in only 23%. The characteristics of a higher proportion of hemorrhagic onset and a lower percentage of cases treated with radical embolization are consistent with our results, except for the difference in the sex distribution. Further clarification of the characteristics of cervical vascular lesions are likely with additional improvements in diagnostic accuracy.

Prognostic factors for SDAVF
----------------------------

A mRS score of 0--2 on day 30 was achieved in 60.5% of the SDAVF cases, suggesting that endovascular treatment of symptomatic lesions does not result in a complete recovery of spinal cord function. A mRS score of 0--2 on day 30 was significantly correlated with only a pre-treatment mRS of 0--2 in univariate analyses. Thus, timely diagnosis and the early treatment of mild symptoms are important.

Study limitation
----------------

Our study had some limitations. Since this study was a subgroup analysis of the JR-NET2 and 3, the follow-up period was set at 30 days, corresponding to the follow-up period for various cerebrovascular disease. However, a follow-up period of 30 days might have been too short to evaluate neurological symptoms definitively in patients with spinal vascular lesions. The diagnosis of the vascular lesions was performed by the participating centers, and the angioarchitectures of the lesions were not examined by central investigators. Thus, some of the lesions might have been incorrectly diagnosed because of the complexity of these lesions. Kiyosue et al.^[@B17]^ and the JSNET Spinal AV Shunts Study Group reported a retrospective analysis of the angiographic and clinical characteristics of 168 cases of thoracolumbar spinal epidural and DAVF in Japan. They found that 49% of spinal epidural AVFs were incorrectly diagnosed as SDAVF at individual centers.

Conclusion
==========

Spinal dural arteriovenous fistula is the most common spinal vascular lesion in Japan, and endovascular treatment has been safely administered. The incidence of cervical SDAVF, which has more aggressive features than non-cervical lesions, has been increasing. Complete obliteration of the shunt was the only predictor of postoperative neurological improvement. Early diagnosis and complete obliteration of the shunt are important for improving the treatment outcome of SDAVF.

This study was supported in part by a Grant-in-Aid (Junkanki-Kaihatsu H24-4-3) from the National Cerebral and Cardiovascular Center, Japan and by Hatazaki Foundation, Kobe, Japan.

The JR-NET3 Study Group: Co-Principle investigator; Nobuyuki Sakai, Kobe City Medical Center General Hospital, Kobe, Japan: Koji Iihara, Kyushu University, Fukuoka, Japan, Tetsu Satow, National Cerebral and Cardiovascular Center, Suita, Japan; Investigators; Masayuki Ezura, Sendai Medical Center, Sendai, Japan, Akio Hyodo, Dokkyo Medical University Saitama Medical Center, Koshigaya, Japan, Shigeru Miyachi, Aichi Medical University, Aichi, Japan, Susumu Miyamoto, Kyoto University, Kyoto, Japan, Yoji Nagai, Kobe University, Kobe, Japan, Kunihiro Nishimura, National Cerebral and Cardiovascular Center, Suita, Japan, Kazunori Toyoda, National Cerebral and Cardiovascular Center, Suita, Japan; Co-investigators; Toshiyuki Fujinaka, Osaka Medical Center, Osaka, Japan, Toshio Higashi, Fukuoka University, Fukuoka, Japan, Masaru Hirohata, Kurume University, Kurume, Japan, Japan, Akira Ishii, Kyoto University, Kyoto, Japan, Hirotoshi Imamura, Kobe City Medical Center General Hospital, Kobe, Japan, Yasushi Ito, Shinrakuen Hospital, Niigata, Japan, Naoya Kuwayama, Toyama University, Toyama, Japan, Hidenori Oishi, Juntendo University, Tokyo, Japan, Yuji Matsumaru, Tsukuba University, Tsukuba, Japan, Yasushi Matsumoto, Konan Hospital, Sendai, Japan, Ichiro Nakahara, Fujita Medical University, Aichi, Japan, Chiaki Sakai, Hyogo College of Medicine, Nishinomiya, Japan, Kenji Sugiu, Okayama University, Okayama, Japan, Tomoaki Terada, Showa University Fujigaoka Hospital, Kanagawa, Japan, Shinichi Yoshimura, Hyogo College of Medicine, Nishinomiya, Japan, and Certified Specialist of Japanese Society of Neuroendovascular Therapy.

**Conflicts of Interest Disclosure**

The authors report no conflict of interest relevant to the research. All authors who are members of The Japan Neurosurgical Society have registered online Self-reported COI Disclosure Statement Forms.

![172 cases of SDAVFs enrolled in JR-NET 2 and 3 were assessed in this study. SDAVF: spinal dural arteriovenous fistula, SPAVF: spinal perimedullary arteriovenous fistula, SIAVM: spinal intramedullary arteriovenous malformation, JR-NET: Japanese Registry of Neuroendovascular Therapy.](nmc-59-492-g1){#F1}

###### 

Comparison of characteristics between cervical SDAVF and other locations

  Diagnosis (*n*)                 Total SDAVF   Cervical (*n* = 24)   Non-cervical (*n* = 148)   Univariate analysis   
  ------------------------------- ------------- --------------------- -------------------------- --------------------- --------
  Sex                             M             133                   15                         118                   0.03
  F                               39            9                     30                                               
  Age                                           62.5                  54.7                       63.8                  0.22
  Pre-symptomatic mRS 0--2        114 (66.3)    21                    93                         0.03                  
  Location (%)                    C             24 (14.0)             24                         \-                    
  Th                              80 (46.5)     \-                    80                                               
  L or S                          64 (37.2)     \-                    64                                               
  Multiple                        4 (2.3)       \-                    4                                                
  Number of feeders (%)           Single        68 (39.5)             6                          62                    0.17
  Multiple                        100 (58.1)    17                    83                                               
  Symptom (%)                     Hemorrhagic   15 (8.7)              10                         5                     \<0.01
  Non-hemorrhagic                 153 (89.0)    11                    142                                              
  Asymptomatic                    3 (1.7)       3                     0                                                
  Strategy of embolization (%)    Radical       136 (79.1)            15                         121                   0.03
  Palliative                      33 (19.2)     9                     24                                               
  Presurgical                     3 (1.7)       0                     3                                                
  Obliteration of nidus^\*^ (%)   Total         94 (54.7)             6                          88                    \<0.01
  Subtotal                        38 (22.1)     9                     29                                               
  Partial                         20 (11.6)     7                     14                                               
  Unchanged                       8 (4.7)       1                     7                                                
  Neurological outcome (%)        Improved      83 (48.3)             6                          77                    0.03
  Stable                          81 (47.1)     14                    67                                               
  Worsen                          5 (2.9)       4                     1                                                
  Complication (%)                12 (7.0)      6                     6                          \<0.01                
  30 Days mRS 0--2 (%)            104 (60.5)    17                    87                         0.37                  

SDAVF: spinal dural arteriovenous fistula.

###### 

Analysis of SDAVF factors correlated with mRS of 0--2 on day 30

                                            Univariate analysis (*P*)
  ----------------------------------------- ---------------------------
  Sex (female)                              0.98
  Age                                       0.78
  Pre-symptomatic mRS (0--2)                \<0.01
  Location (cervical)                       0.56
  Number of feeders (single)                0.3
  Symptom (non-hemorrhagic)                 0.22
  Strategy of embolization (radical)        0.19
  Technical outcome (success)               0.85
  Obliteration of nidus (total occlusion)   0.36
  Neurological outcome (improved)           0.79
  Complication (−)                          0.26

SDAVF: spinal dural arteriovenous fistula.

###### 

Analysis of SDAVF factors correlated with post-operative neurological improvement

                                            Univariate analysis (*P*)   Multivariate logistic regression test
  ----------------------------------------- --------------------------- ------------------------------------------
  Sex (female)                              0.89                        
  Age                                       0.22                        
  Pre-symptomatic mRS (0--2)                0.93                        
  Location (non-cervical)                   0.012                       *P* = 0.48, OR 0.63, 95% CI 0.18--2.24
  Number of feeders (single)                0.62                        
  Symptom (non-hemorrhagic)                 0.01                        *P* = 0.11, OR 0.23, 95% CI 0.04--1.37
  Strategy of embolization (radical)        \<0.01                      *P* = 0.14, OR 2.32, 95% CI 0.75--7.19
  Technical outcome (success)               0.13                        
  Obliteration of nidus (total occlusion)   \<0.01                      *P* = 0.001, OR 4.35, 95% CI 1.84--10.31
  Complication (−)                          0.92                        
